Abstract
Bone sarcomas cause disproportionate morbidity and mortality and desperately need new therapies as there has been little improvement in outcomes in 20 years. Identification of critical signaling pathways, including type 1 insulin-like growth factor receptor (IGF-1R) for Ewing sarcoma and possibly osteosarcoma, and the ERBB and the Wnt signaling pathways for osteosarcoma, have emerged as receptors mediating vital signals for bone sarcoma. Akt, mammalian target of rapamycin (mTOR), phosphoinositide 3-kinases, mitogen-activated protein kinase kinase, extracellular signal-regulated kinases, and Ras pathway play key roles in at least some tumors, and inhibition of mTOR in particular will likely lead to improved survival, although clinical trials are still underway. The Notch pathway and ezrin are essential for osteosarcoma metastasis, and Fas down-regulation is necessary for survival of metastases in lungs. As little is known about chondrosarcoma signaling, more preclinical work is needed. By defining vital signaling pathways in bone sarcomas, small molecule inhibitors can be applied rationally, leading to longer survival and reducing morbidity and late effects from intensive chemotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Kim SY, Toretsky JA, Scher D, Helman LJ: The role of IGF-1R in pediatric malignancies. Oncologist 2009, 14:83–91.
Britten CD: Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 2004, 3:1335–1342.
Ren L, Hong SH, Cassavaugh J, et al.: The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009, 28:792–802.
Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7:1347–1354.
Shih I-M, Wang T-L: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007, 67:1879–1882.
Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635–2643.
Greil R, Anether G, Johrer K, Tinhofer I: Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J Leukoc Biol 2003, 74:311–330.
Pompetti F, Rizzo P, Simon RM, et al.: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63:37–50.
Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422–441.
Toguchida J, Yamaguchi T, Dayton SH, et al.: Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992, 326:1301–1308.
Yokoyama R, Schneider-Stock R, Radig K, et al.: Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 1998, 194:615–621.
Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994, 54:2803–2807.
Kolb EA, Gorlick R, Houghton PJ, et al.: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190–1197.
Hughes DPM, Thomas DG, Giordano TJ, et al.: Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004, 64:2047–2053.
Wen YH, Koeppen H, Garcia R, et al.: Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 2007, 38:1184–1191.
Messerschmitt PJ, Rettew AN, Brookover RE, et al.: Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008, 466:2168–2175.
Hingorani P, Zhang W, Gorlick R, Kolb EA: Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009, 15:3416–3422.
Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001–6007.
Ory B, Blanchard F, Battaglia S, et al.: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007, 71:333–343.
Ferrari S, Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007, 19:341–346.
Yang R, Piperdi S, Gorlick R: Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 2008, 14:6396–404.
Hall-Geryk M YY, Hughes DPM: Inhibiting farnesylation in osteosarcoma [abstract 3759]. Presented at the 99th Annual Meeting of the American Association of Cancer Research. San Diego, CA; April 12–16, 2008.
Woessmann W, Chen X, Borkhardt A: Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol. 2002, 50:397–404.
Ory B, Moriceau G, Redini F, Heymann D: mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem 2007, 14:1381–1387.
Wan X, Mendoza A, Khanna C, Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005, 65:2406–2411.
Gautreau A, Poullet P, Louvard D, Arpin M: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. PNAS 1999, 96:7300–7305.
Wan X, Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12:1007–1018.
Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM: Critical role of Notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008, 14:2962–2969.
Engin F, Bertin T, Ma O, et al.: Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009, 18:1464–1470.
Tanaka M, Setoguchi T, Hirotsu M, et al.: Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009, 100:1957–1965.
Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000, 268:243–248.
Hoang BH, Kubo T, Healey JH, et al.: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004, 109:106–111.
Chen K, Fallen S, Abaan HO, et al.: Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 2008, 51:349–355.
Lee N, Smolarz AJ, Olson S, et al.: A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007, 97:1552–1559.
Koshkina NV, Khanna C, Mendoza A, et al.: Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007, 5:991–999.
Gordon N, Arndt CA, Hawkins DS, et al.: Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005, 27:611–615.
Gordon N, Koshkina NV, Jia S-F, et al.: Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007, 13:4503–4510.
Hou P, Ji M, Yang B, et al.: Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006, 106:1602–1609.
Lim S, Yang MH, Park JH, et al.: Inactivation of the RASSF1A in osteosarcoma. Oncol Rep 2003, 10:897–901.
Schaefer KL, Eisenacher M, Braun Y, et al.: Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008, 44:699–709.
Toretsky JA, Kalebic T, Blakesley V, et al.: The insulin-like growth factor-i receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822–308227.
Scotlandi K, Manara MC, Nicoletti G, et al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868–3876.
Atzori F, Tabernero J, Cervantes A, et al.: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract]. ASCO Meeting Abstracts 2008, 26:3519.
Kang H-G, Jenabi JM, Zhang J, et al.: E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007, 67:3094–3105.
Dalal S, Berry AM, Cullinane CJ, et al.: Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing’s sarcoma family. Clin Cancer Res 2005, 11:2364–2378.
Reddy K, Zhou Z, Jia SF, et al.: Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing’s sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 2008, 123:831–837.
Zhou Z, Bolontrade MF, Reddy K, et al.: Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007, 13:4867–4873.
Uren A, Wolf V, Sun YF, et al.: Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004, 43:243–249.
Guan H, Zhou Z, Gallick GE, et al.: Targeting Lyn inhibits tumor growth and metastasis in Ewing’s sarcoma. Mol Cancer Ther 2008, 7:1807–1816.
Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC: Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6:599–607.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Geryk-Hall, M., Hughes, D.P.M. Critical signaling pathways in bone sarcoma: Candidates for therapeutic interventions. Curr Oncol Rep 11, 446–453 (2009). https://doi.org/10.1007/s11912-009-0061-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-009-0061-z